In this April 2026 YouTube video, primary‑care physician Dr. Ashley Frazee provides a detailed, non‑medical‑advice overview of Foundeo (orforglipron), the first oral small‑molecule GLP‑1 receptor agonist launched by Eli Lilly. She explains how Foundeo differs from earlier peptide‑based GLP‑1 therapies (injectables and oral semaglutide) by being a small molecule that is absorbed reliably without fasting or special timing. The video compares weight‑loss efficacy: Foundeo achieves ~12‑15 % loss, similar to semaglutide, while tirzepatide and retatrutide reach 20‑22 % due to additional GIP and glucagon activity. Dr. Frazee discusses side‑effect profiles, emphasizing dose‑dependent nausea, constipation, diarrhea, and rare hair thinning, and stresses the importance of using the minimum effective dose (not exceeding ~9 mg to avoid GI protest). She outlines contraindications (medullary thyroid cancer risk, pancreatitis, gallstones) and secondary risks such as kidney injury from low fluid intake. The physician adds practical advice on sodium balance, electrolyte supplementation (Element), and resistance training to preserve muscle during weight loss. Pricing is presented via LillyDirect: $149–$349 /month, comparable to injectable Ozempic/Wegovy and cheaper than tirzepatide. She reflects on market impact, suggesting the pill improves access but may not match the potency of multi‑agonist injectables. The video concludes with a call for viewers to consider personal barriers (needle aversion) and to maintain healthy habits, ending with a sponsorship disclosure.
Chapters
Everyone's talking about the pill that replaces GLP-1 shots, and I get it. No needles, none of this, no refrigeration, just a pill. But here's what almost nobody is talking about. A more convenient drug is not automatically a better drug. And if you're switching from an injectable to Foundeo because you think you're upgrading, you might be trading real results for convenience. I'm Dr. Ashley Frazee. I'm a primary care physician, and I've treated hundreds of people with the GLP drugs. And you can say that I'm pretty for the GLP-1s. At this point, based on what I've seen today, let's talk about Foundeo and what it is, how it actually works, where it wins, where it doesn't, and what you need to know before you try it. And you need to know that this is not medical advice. I am just a doctor on the internet. I am not your doctor, but let's get into it. What is Foundeo and why is it different? Well, Foundeo is the brand name for orforglipron. It launched this month, April 2026, through Eli Lilly. It's a GLP-1 receptor agonist, same target as semaglutide or Ozempic or Wegovy. The mechanism in your brain and your gut, slowing digestion, increasing fullness, improving insulin signaling, that's all familiar territory. But here's what makes it genuinely different. Every GLP-1 before this has been a peptide, and peptides, because they're amino acids by nature, look like food to your stomach. So getting them through the gut intact requires workarounds, usually injections that bypass digestion entirely. So Foundeo is not a peptide, and it is not semaglutide. It's a small molecule like most medications, so your stomach doesn't recognize it as food. It doesn't try to digest it, and it passes through the gut lining into the bloodstream reliably, with or without food. No fasting, no timing, no needles. That's the actual innovation here. It's not that we found a better GLP-1, it's that we finally got a GLP-1 into a pill that works like a pill is supposed to. And people keep comparing Foundeo to oral semaglutide, which is Rybelsus or the oral version of Wegovy, and the comparison just isn't even close. The oral semaglutide is a peptide crammed into a pill with a lot of engineering to survive the gut. You have to take it on an empty stomach with no more than 4 ounces of water, wait 30 minutes before eating or drinking anything else, and even then absorption is highly variable. One morning it can work well and one morning it doesn't. And honestly, there were a lot of issues getting people to like Rybelsus. It uses a special co-formulation called Snack, which I think is funny, to force the semaglutide peptide through the gut lining. But this process is incredibly fragile. And so if a person took it with too much water or ate a cracker 20 minutes later instead of 30, well, the absorption just plummeted. From what I remember, people were also having a hard time getting it approved. It cost a lot, and it was only approved for type 2 diabetes. And then tirzepatide came out, and people were just over Rybelsus. So here are the big differences with Foundeo. Supposedly, you can take it anytime— with food, without food, with your coffee, your whiskey, whatever. And that absorption is consistent and predictable. And that matters enormously for how the drug actually performs day to day. It can be consistent. But let's pit Foundeo against the injectable GLP drugs. Here's where I'm going to get real honest with you, because this is the real conversation that needs to be had. Foundeo is a single GLP-1 agonist. Semaglutide is a single GLP-1 agonist. On paper, they're doing the same thing, and the weight loss data in the studies reflects that— around 12 to 15% weight loss. Tirzepatide, the GLP-1 GIP agonist, Agonist peptide shows 20 to 22% average weight loss in the studies, which is not a small difference. And people have less nausea and constipation and just a general better outcome with tirzepatide. Not everyone, but in general. And of course now there's retatrutide, or retatrutide, however you say it, which I've done a whole video on, which is a triple GLP-1, GIP, and glucagon receptor agonism. And the glucagon piece basically prevents your metabolism from downregulating during weight loss. And that's a really big deal for long-term results because with my semaglutide patients, the hardest part of getting them off of semaglutide once they achieved weight loss was that their metabolism was tanked, meaning their metabolic set point for how many calories they burned at rest was much lower than when they started the drug. And then they regained weight pretty easily. So the pill wins on convenience, but the injectables, particularly the other GLPs, tirzepatide and retatrutide, still win on raw potency and efficacy. Now, is there somebody that Foundeo is the right choice for? Absolutely. I mean, if someone is avoiding all the GLPs specifically because of the needles, and that's the real barrier, then getting someone on a GLP-1 in general who needs it is infinitely better than them being on nothing. So convenience can drive compliance, and compliance can drive real outcomes. But if you're somebody who's already on tirzepatide or something similar and losing weight already, and you want to switch to Foundeo because it's a pill, well, just think about the things we just discussed and whether it would be worth it. Now, I briefly went over this, but semaglutide is just not as popular as the other GLP injectables. Due to its high side effect profile. And here's what you need to know about side effects of Foundeo. Basically, you get the same side effects. The trials involved over 4,500 people. And at the higher doses, around 9 milligrams and above, there was quite a bit of nausea, constipation, and even diarrhea. About 10% of the really high dose users stopped using the drug entirely because of the side effects. And there's also a dose dependency issue that I think is really important. So when you look at the data, the side effects jump significantly once you move above That 9 milligrams. So the goal here, as with all the GLPs, is not maximum dose, it's minimum effective dose. You have to find the dose where the metabolic signaling works without your gut staging a full protest. You have to be patient on GLPs. Faster is not always better. In the studies, they did notice hair thinning. Around 5% of the users reported that, which happens when your body goes through rapid weight loss in general. And then of course, when prescribing these things, we always have to note you cannot take it if you have a history of medullary thyroid cancer or a thyroid C-cell tumor risk. This is just a black box warning on it. And then there's still the risk of pancreatitis and gallstones. Gallstones also apply for people with rapid weight loss. Because nausea can lead to poor fluid intake, There's a secondary kidney injury risk if you're not drinking enough water. Speaking of, I want to touch on lowering insulin and the downstream effects that that has on sodium. So this applies to anyone on any of the GLPs, whether you're overweight or not. When you have low insulin, your kidneys end up dumping sodium, and this can lead to a feeling of fatigue and sluggishness. We've seen this a lot on the GLPs, especially with exercise. I actually have an issue where I don't eat a lot during the day, and I don't drink enough water, and then sometimes I go to work out and just royally drag. It's because of this same issue, not a GLP, but low insulin leads to low sodium, which can lead to low energy. And so if you're doing something that lowers your insulin, getting the proper amount of sodium can be really helpful. And again, even though my problem isn't due to GLPs, I still have A low insulin issue sometimes, and I end up drinking a lot of Element. So this is 1,000 milligrams of sodium with potassium and magnesium, which those are important for muscular endurance. And Element agreed to sponsor this video, so thank you to Element. I've been drinking this stuff basically since I started lifting weights, and I wanted to share that with you. Right now, Element is offering my viewers a free 8-count sample pack of their most popular flavors with any order. This is a great way to try the favorite flavors. I'm really into the mango Or you can share it with your friend. You can get yours at drinkelement.com/my last name, which is Frazee, or Froese, or however you want to say it. This deal is only available through my link. So back to our show. Let's talk about the cost because this is important. This is where Foundeo is actually doing something interesting. So Eli Lilly has come out with aggressive pricing through LillyDirect. The starting dose of Foundeo, which is 0.8 milligrams, is around $149 a month, and the highest dose is $349 a month, which is pretty comparable to the injectable Ozempic or Wegovy and way less expensive than tirzepatide or Zepbound. I share the cash prices because it's cool if your insurance will cover it. I mean, I just don't like to deal with insurance. So the reason that this pricing matters is that Lilly is clearly trying to compete with the compounding pharmacies that it's been Suing. That whole ecosystem exploded because people couldn't afford or access the injectables, especially when they went on shortage. Well, if the oral pill is accessible, convenient, and reasonably priced, that changes the landscape for them. You can be angry because they're Big Pharma, but I think it was a smart move. The bottom line is that Foundeo is a real advancement, not because it's more powerful, but maybe we'll see other GLPs move in this direction too. Comment your thoughts. If you're already on a dual or triple agonist and doing well, not that you're supposed to be on the triple agonist yet. It's not approved for human use, you know. Well, I wouldn't automatically chase the convenience. I mean, what we've seen so far, the more targets, the more weight loss, the more metabolic benefit, and that math is still holding. But just remember, regardless of which one you're on or not, please be lifting weights or doing some sort of resistance training and eat enough protein. I mean, hold on to your muscle mass. Don't lose too much of it and become frail on a weight loss. I'm Dr. Ashley Frazee. I'm just a doctor with a passion for understanding things and passing the information on to you. If this video was useful for you, please hit like for me, subscribe to my channel, and tell me in the comments, are you team pill or team injection? Because I genuinely want to know where people are landing on this. I hope you have the best day.
